世界の抗うつ薬市場は、2021年の184億ドルから2030年までに335億ドルを超え、今後数年間、つまり2021年から31年のCAGRは6.16％と推定されます。うつ病の発生数の増加、高齢人口の急増、および副作用の少ない医薬品の開発のための新しい技術の出現が市場を後押しします。さらに、病状や必要な臨床的ニーズに関する意識の高まり、そしてストレスに悩む人々の増加などが抗うつ薬市場の成長を促す要因となります。
目次
Contents
1. Executive Summary
2. Global Antidepressant Drugs Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Global Antidepressant Drugs Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Global Antidepressant Drugs Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. Global Antidepressant Drugs Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. By Depressive Disorder: Market Share (2020-2030F)
13.1. Major Depressive Disorder, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.2. Obsessive-Compulsive Disorder, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.3. Generalized Anxiety Disorder, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.4. Cross Traffic Alert, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.5. Panic Disorder, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14. By Products: Market Share (2020-2030F)
14.1. Tricyclic Antidepressants, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.2. Selective Serotonin Reuptake Inhibitors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.3. Serotonin-Norepinephrine Reuptake Inhibitors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.4. Monoamine Oxidase Inhibitors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.5. Serotonin Antagonist and Reuptake Inhibitors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
15. Company Profile
15.1. Allergan PLC
15.1.1. Company Overview
15.1.2. Company Total Revenue (Financials)
15.1.3. Market Potential
15.1.4. Global Presence
15.1.5. Key Performance Indicators
15.1.6. SWOT Analysis
15.1.7. Product Launch
15.2. AstraZeneca
15.3. Eli Lilly and Company
15.4. GlaxoSmithKline PLC
15.5. H. Lundbeck AS
15.6. Johnson & Johnson
15.7. Pfizer Inc.
15.8. Merck & Co. Inc.
15.9. Sanofi
15.10. Sun Pharmaceuticals Pvt Ltd
15.11. Alkermes
15.12. Bristol Myers Squibb Company
15.13. Teva Pharmaceutical Industries
15.14. Eli Lilly and Co.
15.15. Takeda Pharmaceutical Co. Ltd
15.16. Forest laboratories
15.17. Akeda Pharmaceutical
15.18. Other Prominent Players
Consultant Recommendation
The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
